Please assess the completion status of the following clinical trial:

Trial Title: Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. age:18-75 years, male or femal.~2. Histologically confirmed primary Squamous Cell Carcinoma of the Esophagus,Local advanced esophageal cancer diagnosed by pathology and imaging,clinical stage T3-4N0M0, T1-4N+M0,Ⅱ-Ⅳa.~3. Pre-treatment evaluation can not tolerate concurrent radiochemotherapy or rejection of the concurrent use of chemotherapy with radiotherapy.~4. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.~5. ECOG 0-1.~6. Adequate organ function.~7. Life expectancy of greater than 6 months.~8. Patient has given written informed consent.~Exclusion Criteria:~1. Patients who have or are currently undergoing additional chemotherapy, radiation therapy, targeted therapy or immunotherapy.~2. Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation.~3. Subjects before or at the same time with other malignant tumors (except which has cured skin basal cell carcinoma and cervical carcinoma in situ);~4. Subjects with any active autoimmune disease or history of autoimmune disease~5. Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;~6. Active infection or an unexplained fever \> 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);~7. Received a live vaccine within 4 weeks of the first dose of study medication.~8. Pregnancy or breast feeding.~9. Decision of unsuitableness by principal investigator or physician-in-charge.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SHR-1210+ Radiotherapy (Type: EXPERIMENTAL): Radiotherapy,intensity modulated radiation therapy (IMRT), 54-60 Gy, 1.8-2.0 Gy per fraction ,5 fractions per week, for 6 weeks. Radiation begun the day after the first dose of SHR-1210. SHR-1210 (200mg fixed dose every 2 weeks, one cycle is four weeks, total 8 cycles ) will be administered as an intravenous infusion over 30 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).